Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA May 12, 2026
Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer May 12, 2026
Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform May 12, 2026
Kanvas Biosciences Secures $48M Series A to Deliver Novel Microbiome Therapeutics to Cancer Patients May 12, 2026
TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
ADCE-T02 enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors April 28, 2026
Promising Clinical Activity and Favorable Safety Profile Reported for ACE-106 in solid tumors April 21, 2026
C4 Therapeutics and Roche Enter New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing for Global Development of Solid Tumor CAR-T Therapies April 15, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First-Patient-In for Ph 1 Trial of IDE574 in Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer April 7, 2026
First-Patient-In for Ph 1 Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma April 7, 2026
